The improved understanding of the molecular mechanisms that drive tumorigenesis has led to the development of molecularly targeted agents (MTAs) that inhibit specific proteins or pathways. However, the rate of drug approvals remains disappointingly low in oncology. The authors of this Review discuss several aspects of phase I trials that are evolving in the MTA era in order to adapt to the changing nature of cancer therapies and to expedite their clinical translation.
- Kit Man Wong
- Anna Capasso
- S. Gail Eckhardt
